查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677241

细胞和基因治疗的个人化奈米技术市场（按治疗类型、奈米技术类型、应用和最终用户划分）- 2025-2030 年全球预测

Personalized Nanotechnology for Cell & Gene Therapies Market by Therapy Type, Nanotechnology Type, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

个人化细胞和基因治疗奈米技术市场预计在 2024 年价值为 8.5508 亿美元，在 2025 年增长至 10.0566 亿美元，复合年增长率为 19.29%，到 2030 年将达到 24.6462 亿美元。

主要市场统计数据
基准年 2024 年 8.5508亿美元
预计 2025 年 10.566亿美元
预测年份 2030 24亿6462万美元
复合年增长率（%） 19.29％

个人化奈米技术在细胞和基因治疗领域的出现代表了现代医学的一个令人兴奋的前沿。这种创新的融合为根据每个患者的特定需求制定治疗方法铺平了道路，从而提高了治疗的精确度和疗效，同时注重最大限度地减少副作用。近年来，生物技术和奈米工程的快速发展为曾经无法想像的突破创造了肥沃的土壤。透过利用奈米材料和设备的独特特性，研究人员现在能够以传统方法无法达到的精度瞄准患病细胞。这种模式转移正在激发药物传输、诊断技术和再生治疗策略的新途径，所有这些都有助于实现更具活力和灵活性的医疗保健方法。

这些尖端技术的融合不仅是科学好奇心的产物，也是对紧急临床需求的回应。改善患者治疗效果、克服抗药性以及降低全身性毒性的潜力只是个人化奈米技术提供的一些好处。随着该领域的不断发展和演变，治疗格局正在迅速改变，为复杂疾病提供更具适应性和更有效的治疗。这项介绍性探索为深入探讨推动这场医学革命的各种力量和因素奠定了基础。

改变细胞和基因治疗个人化奈米技术市场

在过去的几年里，细胞和基因治疗领域发生了巨大的变化，正在重塑治疗方法的未来。奈米製造和分子工程技术的进步处于这些变化的前沿。奈米级创新正在融入治疗流程中，不仅提高了药物传递的精确度，而且还实现了针对性干预，从源头解决基因异常和细胞功能障碍。这种转变是精准医疗趋势的一部分，精准医疗是指根据个人基因组成和疾病特征的独特特征来制定治疗方案。

研发方面的投资正在加速创新并有助于缩小奈米技术理论应用与实际临床实施之间的差距。学术机构、生技公司和监管机构之间的合作努力正在培育蓬勃发展的创新生态系统，并确保突破性技术转化为可行的治疗解决方案。这个变革时代的特点是多学科伙伴关係、大量资本投入、以及透过奈米技术与细胞和基因疗法的融合改善患者治疗结果的不懈努力。随着传统治疗模式的演变，行业领导者越来越认识到采用具有扩充性、适应性和改善治疗结果的新技术的价值。

推动市场创新的关键区隔洞察

了解不断发展的市场的关键是全面考虑突出个性化奈米技术不同方面的细分见解。市场根据治疗方法类型进行明显细分，重点关注细胞和基因治疗，从而在每个领域都有利基研究。在细胞治疗方面，免疫细胞治疗、诱导性多功能干细胞、间质干细胞、干细胞治疗等创新治疗方法正在研究和应用。同样，基因治疗也受到 CRISPR 技术、尖端传递机制、实现精确基因组编辑的基因改造方法以及非病毒载体的开发等先锋方法的推动。

根据奈米技术的类型对市场进行进一步细分。这包括对奈米载体设计的深入评估、奈​​米设备复杂程度的进步、奈米封装技术的细微差别以及奈米材料的新兴作用。除了这些技术进步之外，还有对奈米医学应用和奈米结构构造成像的深入了解，它们都为个人化医疗的进步做出了独特的贡献。此外，针对癌症治疗、心血管疾病、遗传性疾病和神经系统疾病的针对性干预正在创造多维治疗方法。最后，按最终用户细分拓宽了市场视角，因为诊断中心、医疗机构、製药公司和研究机构在推动需求和培育创新环境方面都发挥着关键作用。这些综合的见解全面概况了不同领域如何共同引领个人化奈米治疗解决方案的未来。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球慢性病发生率不断上升
      • 全球范围内精准医疗的采用正在增加
      • 政府和监管部门的支持将鼓励奈米技术应用的研究和创新
    • 限制因素
      • 与细胞和基因治疗奈米技术相关的高水平研发
    • 机会
      • 口服基因治疗中奈米技术的持续创新
      • 靶向奈米递送系统的开发
    • 任务
      • 应对细胞和基因治疗个人化奈米技术的复杂监管问题
  • 市场区隔分析
    • 治疗类型：个人化治疗对免疫细胞疗法的需求日益增加
    • 应用：奈米技术在癌症治疗中的重要性日益增加
  • 波特五力分析
  • PESTEL 分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

6. 细胞和基因疗法个人化奈米技术市场（按治疗类型划分）

  • 细胞疗法
    • 免疫细胞疗法
    • 诱导多功能细胞
    • 间质干细胞
    • 干细胞治疗
  • 基因治疗
    • CRISPR 技术
    • 传递机制
    • 基因改造方法
    • 非病毒载体

7. 细胞和基因治疗的个人化奈米技术市场（以奈米技术类型）

  • 奈米载体设计
  • 奈米装置
  • 奈米封装
  • 奈米材料
  • 奈米医学
  • 奈米结构构造成像

8. 细胞和基因治疗的个人化奈米技术市场（按应用）

  • 癌症治疗
  • 心血管疾病
  • 遗传性疾病
  • 神经系统疾病

9. 终端用户细胞和基因治疗个人化奈米技术市场

  • 诊断中心
  • 医疗设施
  • 製药公司
  • 研究所

10. 美洲细胞与基因治疗个人化奈米技术市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区细胞和基因治疗个人化奈米技术市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲细胞和基因治疗个人化奈米技术市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • AbbVie Inc.
  • Amgen Inc.
  • Arcturus Therapeutics, Inc.
  • AstraZeneca PLC
  • BASF Pharma Solutions
  • BlueWillow Biologics Inc.
  • Bristol-Myers Squibb Company
  • Camurus AB
  • Celgene, Inc.
  • Cristal Therapeutics
  • Cytimmune Sciences
  • Eisai Co., Ltd.
  • EyePoint Pharmaceuticals
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Nanobiotix SA
  • Novartis AG
  • Pfizer Inc.
  • Spark Therapeutics, Inc.
  • Teva Pharmaceutical Industries Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-094390F3D2A6

The Personalized Nanotechnology for Cell & Gene Therapies Market was valued at USD 855.08 million in 2024 and is projected to grow to USD 1,005.66 million in 2025, with a CAGR of 19.29%, reaching USD 2,464.62 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 855.08 million
Estimated Year [2025] USD 1,005.66 million
Forecast Year [2030] USD 2,464.62 million
CAGR (%) 19.29%

The emergence of personalized nanotechnology in the realm of cell and gene therapies marks an exciting frontier in modern medicine. This innovative convergence is paving the way for therapies that are finely tailored to individual patient needs, thereby offering enhanced precision and efficacy with a focus on minimizing adverse effects. In recent years, rapid advances in both biotechnology and nanoscale engineering have created a fertile ground for breakthroughs that once seemed unthinkable. By harnessing the unique properties of nanomaterials and devices, researchers are now able to target diseased cells with a level of accuracy that traditional methods could not achieve. This paradigm shift has spurred new avenues for drug delivery, diagnostic techniques, and regenerative treatment strategies, all of which are contributing to a more dynamic and responsive approach to healthcare.

The integration of these advanced technologies is not merely a product of scientific curiosity but a response to pressing clinical needs. Improved patient outcomes, the ability to overcome drug resistance, and the potential for reducing systemic toxicity are just a few of the benefits that personalized nanotechnology brings to the table. As this field continues to grow and evolve, it is rapidly transforming the therapeutic landscape by enabling treatments that are more adaptable and effective in combating complex diseases. This introductory exploration sets the stage for a deeper dive into the various forces and factors driving this revolution in medical science.

Transformative Shifts in the Cell & Gene Therapy Landscape

Over the past several years, the landscape of cell and gene therapies has witnessed transformative shifts that are reshaping the future of treatment modalities. Technological advancements in nanofabrication and molecular engineering have been at the forefront of these changes. The integration of nanoscale innovations into therapeutic pipelines is not only improving the precision of drug delivery but is also enabling targeted interventions that can address genetic anomalies and cellular dysfunctions at their very source. These shifts are part of a broader movement towards precision medicine, where treatments are custom-tailored to the genetic makeup and unique characteristics of an individual's disease profile.

Investment in research and development has accelerated innovations, helping to bridge the gap between theoretical nanotechnology applications and practical, clinical implementation. Collaborative efforts between academic institutions, biotech companies, and regulatory agencies are fostering a thriving ecosystem of innovation, ensuring that breakthroughs are translated into viable therapeutic solutions. This era of transformation is marked by cross-disciplinary partnerships, significant capital investments, and an unyielding drive to improve patient outcomes through the integration of nanotechnology with cellular and genetic therapies. As traditional treatment paradigms evolve, industry leaders are increasingly recognizing the value of adopting new technologies that promise scalability, adaptability, and enhanced therapeutic efficacy.

Key Segmentation Insights Driving Market Innovation

A critical aspect of understanding the evolving market is a comprehensive examination of segmentation insights that underscore the various dimensions of personalized nanotechnology. The market is distinctly segmented based on therapy type, where the focus on cell therapy and gene therapy has led to niche studies in each domain. Within cell therapy, research and applications span immune cell therapy, induced pluripotent stem cells, mesenchymal stem cells, and innovative treatments that fall under the broad umbrella of stem cell therapy. Similarly, gene therapy is driven by pioneering approaches that include CRISPR technology, cutting-edge delivery mechanisms, gene modification methods that allow for precise genome editing, and the development of non-viral vectors.

Further refinement of the market occurs through segmentation by nanotechnology type. This includes detailed evaluations of nanocarrier design, the sophistication of nanodevices, the nuances of nanoencapsulation techniques, and the emerging role of nanomaterials. Complementary to these technological advances are insights into nanomedicine applications and nanostructure imaging, each contributing uniquely to the advancement of personalized therapies. The market also differentiates itself based on application, where targeted interventions in cancer therapies, cardiovascular diseases, inherited genetic disorders, and neurological disorders have created a multi-dimensional approach to treatment. Finally, segmentation by end user has expanded the market perspective, with diagnostic centers, healthcare facilities, pharmaceutical companies, and research institutions each playing a pivotal role in driving demand and fostering an innovative environment. These integrated insights provide a comprehensive overview of how distinct segments are collectively steering the future of personalized nanotherapy solutions.

Based on Therapy Type, market is studied across Cell Therapy and Gene Therapy. The Cell Therapy is further studied across Immune Cell Therapy, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, and Stem Cell Therapy. The Gene Therapy is further studied across CRISPR Technology, Delivery Mechanisms, Gene Modification Methods, and Non-Viral Vectors.

Based on Nanotechnology Type, market is studied across Nanocarrier Design, Nanodevices, Nanoencapsulation, Nanomaterials, Nanomedicine, and Nanostructure Imaging.

Based on Application, market is studied across Cancer Therapies, Cardiovascular Diseases, Inherited Genetic Disorders, and Neurological Disorders.

Based on End User, market is studied across Diagnostic Centers, Healthcare Facilities, Pharmaceutical Companies, and Research Institutions.

Key Regional Dynamics Impacting Market Growth

Regional dynamics play a pivotal role in dictating market trends and influencing the adoption of innovative therapeutic solutions. The Americas has emerged as a powerhouse, buoyed by robust investment in research and state-of-the-art healthcare infrastructure. The region benefits from a strong network of academic research institutions and commercial partnerships that catalyze breakthroughs in both cellular and gene therapy fields. Emerging protocols and clinical validations have paved the way for the rapid adoption of personalized nanotechnologies, fostering an environment in which innovation thrives.

In parallel, the Europe, Middle East & Africa region is seeing an upswing in regulatory reforms and collaborative research initiatives, which facilitate accelerated product development. The region's focus on harmonizing regulatory practices and encouraging multinational partnerships is instrumental in moving the market forward. Meanwhile, the Asia-Pacific region has rapidly established itself as a critical hub of technological innovation, bolstered by significant investments in both infrastructure and human capital. Rapid economic growth, combined with a burgeoning biotech industry and increasing government support for high-tech research, highlights the region's potential to become a major player in the global market. Across these regions, the interplay between robust public infrastructure, policy innovation, and strategic investment continues to drive the evolution of personalized nanotechnology applications.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Shaping the Nanotechnology Landscape

An analysis of company-level insights reveals a landscape that is both competitive and forward-thinking. Leading companies in the sector are investing heavily in research and development, strategic collaborations, and acquisitions to strengthen their foothold in personalized therapies. Major corporations such as AbbVie Inc. and Amgen Inc. have set high benchmarks for innovation, while emerging players are steadily gaining ground with niche expertise. Among these innovators, Arcturus Therapeutics, Inc. is noted for its dynamic approach to blending nanotechnology with gene editing techniques, and AstraZeneca PLC continues to be a frontrunner in bridging clinical efficacy with scalable production processes. BASF Pharma Solutions and BlueWillow Biologics Inc. are also making significant contributions by focusing on specialized delivery systems and novel formulation technologies.

Bristol-Myers Squibb Company, Camurus AB, and Celgene, Inc. have managed to capture market attention through robust pipelines that integrate advanced therapeutic protocols. In parallel, Cristal Therapeutics and Cytimmune Sciences offer promising perspectives through their ongoing research in nanostructure applications, while Eisai Co., Ltd. and EyePoint Pharmaceuticals have been instrumental in disruptive drug delivery techniques. Industry giants like Gilead Sciences Inc. and GlaxoSmithKline PLC have continued to innovate, and companies like Hoffmann-La Roche Ltd and Ipsen Pharma are actively refining their therapeutic approaches to meet evolving clinical needs. Johnson & Johnson, Merck KGaA, Nanobiotix SA, Novartis AG, and Pfizer Inc. further enhance the market competitive edge, joined by Spark Therapeutics, Inc., Teva Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc., who collectively are reshaping industry standards and setting the stage for future advancements through collaborative ventures and aggressive research investments.

The report delves into recent significant developments in the Personalized Nanotechnology for Cell & Gene Therapies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Arcturus Therapeutics, Inc., AstraZeneca PLC, BASF Pharma Solutions, BlueWillow Biologics Inc., Bristol-Myers Squibb Company, Camurus AB, Celgene, Inc., Cristal Therapeutics, Cytimmune Sciences, Eisai Co., Ltd., EyePoint Pharmaceuticals, Gilead Sciences Inc., GlaxoSmithKline PLC, Hoffmann-La Roche Ltd, Ipsen Pharma, Johnson & Johnson, Merck KGaA, Nanobiotix SA, Novartis AG, Pfizer Inc., Spark Therapeutics, Inc., Teva Pharmaceutical Industries Limited, and Thermo Fisher Scientific Inc.. Actionable Recommendations for Strategic Market Leadership

For industry leaders navigating this rapidly evolving market, several actionable recommendations can serve as a roadmap for success. The first step is a commitment to continuous innovation, which can be achieved by prioritizing robust research and development initiatives. Companies should actively seek partnerships that combine expertise in nanotechnology with advanced therapies to yield synergies that translate into tangible clinical and economic benefits. Investing in pilot programs and targeted clinical trials can also significantly de-risk emerging technologies and provide a competitive advantage in early adoption.

Moreover, it is crucial to develop a comprehensive strategy that encompasses regulatory compliance, quality assurance, and cybersecurity measures. A proactive approach toward addressing regulatory uncertainties and establishing robust quality control protocols will be essential in building trust with both clinical practitioners and patients. Industry players are encouraged to leverage real-world data analytics and outcome-based research to continually refine their therapeutic approaches. In addition to internal innovations, fostering cross-industry collaborations can open new avenues for investment, shared expertise, and access to emerging markets. In summary, leaders should focus on strengthening their collaborative networks, investing in scalable technologies, and anticipating future market needs by aligning their strategic initiatives with both current and projected regulatory landscapes.

Conclusion: A New Era in Nanotechnology-Enhanced Therapies

In conclusion, the market for personalized nanotechnology in cell and gene therapies is entering a new era marked by robust innovation, dynamic market segmentation, and a global expansion that transcends traditional boundaries. The in-depth analysis of therapy types, technology integrations, and regional trends underscores the transformative potential of these advanced therapeutic modalities. As breakthroughs continue to emerge, the confluence of research excellence and strategic corporate initiatives is driving a significant shift toward more effective, patient-centric treatment options.

The confluence of industry leaders, evolving regulatory frameworks, and technological breakthroughs forms the cornerstone of a future where therapeutic interventions are not only more precise but also significantly more accessible. This evolving landscape presents both challenges and opportunities, compelling market participants to be agile, innovative, and strategically aligned. The journey ahead is one of dynamic growth and ongoing transformation, where continuous learning and adaptation will be key differentiators for those poised to lead the next wave of medical innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases globally
      • 5.1.1.2. Increasing adoption of precision medicine worldwide
      • 5.1.1.3. Government and regulatory support amplifying research and innovations in nanotechnology applications
    • 5.1.2. Restraints
      • 5.1.2.1. High research and development costs associated with nanotechnology in cell and gene therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations in leveraging nanotechnology in orally administered gene therapies
      • 5.1.3.2. Development of targeted nano-delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating regulatory complexities in personalized nanotechnology for cell and gene therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Proliferating need for immune cell therapy for personalized treatments
    • 5.2.2. Application: Rising significance of nanotechnology in cancer therapies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Personalized Nanotechnology for Cell & Gene Therapies Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Cell Therapy
    • 6.2.1. Immune Cell Therapy
    • 6.2.2. Induced Pluripotent Stem Cells
    • 6.2.3. Mesenchymal Stem Cells
    • 6.2.4. Stem Cell Therapy
  • 6.3. Gene Therapy
    • 6.3.1. CRISPR Technology
    • 6.3.2. Delivery Mechanisms
    • 6.3.3. Gene Modification Methods
    • 6.3.4. Non-Viral Vectors

7. Personalized Nanotechnology for Cell & Gene Therapies Market, by Nanotechnology Type

  • 7.1. Introduction
  • 7.2. Nanocarrier Design
  • 7.3. Nanodevices
  • 7.4. Nanoencapsulation
  • 7.5. Nanomaterials
  • 7.6. Nanomedicine
  • 7.7. Nanostructure Imaging

8. Personalized Nanotechnology for Cell & Gene Therapies Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Therapies
  • 8.3. Cardiovascular Diseases
  • 8.4. Inherited Genetic Disorders
  • 8.5. Neurological Disorders

9. Personalized Nanotechnology for Cell & Gene Therapies Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Healthcare Facilities
  • 9.4. Pharmaceutical Companies
  • 9.5. Research Institutions

10. Americas Personalized Nanotechnology for Cell & Gene Therapies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Personalized Nanotechnology for Cell & Gene Therapies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Personalized Nanotechnology for Cell & Gene Therapies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Poseida Therapeutics agreed to be acquired by Roche Holdings
    • 13.3.2. Envoya's nanoparticle technology significantly enhances nucleic acid encapsulation
    • 13.3.3. Cellevate to re-launch its innovative Cellevat3d nanofiber microcarriers
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Arcturus Therapeutics, Inc.
  • 4. AstraZeneca PLC
  • 5. BASF Pharma Solutions
  • 6. BlueWillow Biologics Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Camurus AB
  • 9. Celgene, Inc.
  • 10. Cristal Therapeutics
  • 11. Cytimmune Sciences
  • 12. Eisai Co., Ltd.
  • 13. EyePoint Pharmaceuticals
  • 14. Gilead Sciences Inc.
  • 15. GlaxoSmithKline PLC
  • 16. Hoffmann-La Roche Ltd
  • 17. Ipsen Pharma
  • 18. Johnson & Johnson
  • 19. Merck KGaA
  • 20. Nanobiotix SA
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Spark Therapeutics, Inc.
  • 24. Teva Pharmaceutical Industries Limited
  • 25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET MULTI-CURRENCY
  • FIGURE 2. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET MULTI-LANGUAGE
  • FIGURE 3. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 4. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY IMMUNE CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CRISPR TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY DELIVERY MECHANISMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE MODIFICATION METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NON-VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOCARRIER DESIGN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANODEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOENCAPSULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOMATERIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOMEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOSTRUCTURE IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CANCER THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY INHERITED GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PERSONALIZED NANOTECHNOLOGY FOR CELL & GENE THERAPIES MARKET SIZE, BY NANOTECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN PERSONALIZED NANOTECHNOLOGY FO